miR-302 cluster inhibits angiogenesis and growth of K562 leukemia cells by targeting VEGFA
Authors Cao J, Li L, Han X, Cheng H, Chen W, Qi K, Chen C, Wu Q, Niu M, Zeng L, Xu K
Received 8 October 2018
Accepted for publication 21 November 2018
Published 8 January 2019 Volume 2019:12 Pages 433—441
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Leo Jen-Liang Su
Jiang Cao,1,* Li Li,2,* Xiao Han,1 Hai Cheng,1 Wei Chen,1 Kunming Qi,1 Chong Chen,1 Qingyun Wu,1 Mingshan Niu,1 Lingyu Zeng,1 Kailin Xu1
1Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China; 2Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
*These authors contributed equally to this work
Background: miR-302 cluster has been reported as a tumor suppressor in many human cancers; yet, its function in chronic myeloid leukemia (CML) tumorigenesis remains largely unclear. The study was aimed to explore the functional roles of miR-302 cluster in CML progression.
Materials and methods: Quantitative reverse transcriptase PCR and Western blot were performed to evaluate miR-302 cluster and vascular endothelial growth factor A (VEGFA) expression levels. Cell Counting Kit-8 assay, colony formation assay and human umbilical vein endothelial cell line capillary tube formation were used to determine the influence of miR-302 cluster on the growth and angiogenesis of K562 cells, respectively. Luciferase reporter assay was employed to confirm the direct target interaction between miR-302 cluster and VEGFA.
Results: This study demonstrated that miR-302 cluster was frequently downregulated in CML samples and cell lines and high level of miR-302 cluster was significantly associated with good prognosis of CML patients. Compared with miRNA negative control, miR-302 cluster mimics obviously suppressed cell growth, colony formation and angiogenesis. Further studies revealed that VEGFA was a direct target gene of miR-302 cluster. Moreover, overexpression of VEGFA dramatically abated the inhibition of miR-302 cluster on cell growth and angiogenesis.
Conclusion: The present study, for the first time, identified miR-302 cluster as a tumor suppressor, and overexpression of miR-302 cluster inhibited growth and angiogenesis in K562 cells. miR-302 cluster may be a potential therapeutic target in CML to develop the adjuvant antiangiogenic therapy based on VEGFA.
Keywords: chronic myeloid leukemia, angiogenesis, miR-302, VEGFA
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]